Back to Results
Arthur S. Tischler, MD
Surgical Pathologist; Professor, Tufts University School of Medicine
Department + Services
Pathology and Laboratory Medicine
General surgical pathology, endocrine pathology
Seeing Patients In
||Endocrine pathology and pathobiology, neuroendocrine tumors, especially pheochromocytoma and paraganglioma
|Training + Education
Jefferson Medical College of Thomas Jefferson University; Beth Israel Hospital
||View Accepted Insurances at Tufts MC + Floating Hospital
Tufts Medical Center
800 Washington St.
Boston, MA 02111
Phone #: 617-636-5829
Fax #: 617-636-8302
2015, "Top Doctor," Boston Magazine
2011, Science Award, Pheo Para Alliance
Past-president of Endocrine Pathology Society
Former Editor-in-Chief of Endocrine Pathology
1. Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ, Fojo T, et al. New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. J Clin Oncol. 2013;31:1690-8.
2. Chae YC, Angelin A, Lisanti S, Kossenkov AV, Speicher KD, Wang H, et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nature Communications. 2013;4:2139.
3. Gimenez-Roqueplo AP, Tischler AS. Pheochromocytoma and Paraganglioma: progress on all fronts. Endocr Pathol. 2012;23:1-3.
4. Eisenhofer G, Tischler AS, de Krijger RR. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol. 2012;23:4-14.
Arthur Tischler is a surgical pathologist at Tufts Medical Center and professor of pathology at Tufts University School of Medicine. His research deals with catecholamine-producing adrenal gland neuroendocrine tumors called pheochromocytomas and their extra-adrenal counterparts known as paragangliomas. It encompasses basic and translational aspects of pheochromocytoma biology, with a particular focus on development and application of models for basic and pre-clinical research. Dr Tischler established the widely utilized PC12 rat pheochromocytoma line in a collaborative study with Dr Lloyd Greene in 1976. More recently, mouse pheochromocytoma (MPC) cell lines now used for testing a variety of pre-clinical imaging and treatment modalities were developed in the Tischler laboratory at Tufts Medical Center by Dr. James Powers and Dr. Tischler. Current efforts in the laboratory are focused on developing animal models specifically relevant to often-malignant hereditary pheochromocytomas and paragangliomas caused by mutations of succinate dehydrogenase genes and on establishing human pheochromocytoma/paraganglioma cell lines, which currently do not exist. Dr. Tischler has served as Editor in Chief of the journal Endocrine Pathology and as president of the Endocrine Pathology Society. He was a founding member of the Pheochromocytoma Research and Support Organization (PRESSOR) and currently co-chairs the PRESSOR Tumor Models Working Group. In 2011 he received the annual Science Award from the PheoPara Alliance, a patient advocacy organization supporting research and education of both patients and clinicians.